Thus, although mutations in p53 are also frequent in colon cancer, the fact that Chk1 inhibition can influence cell apoptosis independent of p53 status suggests that a strategy combining Chk1 inhibitors with 5-FU may be a novel alternative to treat CRC with both APC and p53 mutations [23, 25, 33]. The gene discussed is CHEK1; the disease is colorectal carcinoma.